UY40218A - Formas amorfas y cristalinas de los antagonistas de mci-1 - Google Patents
Formas amorfas y cristalinas de los antagonistas de mci-1Info
- Publication number
- UY40218A UY40218A UY0001040218A UY40218A UY40218A UY 40218 A UY40218 A UY 40218A UY 0001040218 A UY0001040218 A UY 0001040218A UY 40218 A UY40218 A UY 40218A UY 40218 A UY40218 A UY 40218A
- Authority
- UY
- Uruguay
- Prior art keywords
- amorphous
- mci
- antagonists
- crystalline forms
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263327656P | 2022-04-05 | 2022-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY40218A true UY40218A (es) | 2023-10-13 |
Family
ID=86386948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001040218A UY40218A (es) | 2022-04-05 | 2023-04-10 | Formas amorfas y cristalinas de los antagonistas de mci-1 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240140966A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4504738A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025511331A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023250874A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3255077A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024012195A (cg-RX-API-DMAC10.html) |
| TW (1) | TW202404982A (cg-RX-API-DMAC10.html) |
| UY (1) | UY40218A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023196361A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119255998A (zh) | 2022-05-04 | 2025-01-03 | 吉利德科学公司 | 特定mcl-1抑制剂的盐和多晶型物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| KR20230113577A (ko) * | 2020-11-25 | 2023-07-31 | 암젠 인크 | 알데히드의 거울상이성질체 선택적 알케닐화 |
-
2023
- 2023-04-05 WO PCT/US2023/017505 patent/WO2023196361A1/en not_active Ceased
- 2023-04-05 AU AU2023250874A patent/AU2023250874A1/en active Pending
- 2023-04-05 EP EP23724439.7A patent/EP4504738A1/en active Pending
- 2023-04-05 CA CA3255077A patent/CA3255077A1/en active Pending
- 2023-04-05 JP JP2024558382A patent/JP2025511331A/ja active Pending
- 2023-04-05 US US18/296,211 patent/US20240140966A1/en active Pending
- 2023-04-06 TW TW112112761A patent/TW202404982A/zh unknown
- 2023-04-10 UY UY0001040218A patent/UY40218A/es unknown
-
2024
- 2024-10-02 MX MX2024012195A patent/MX2024012195A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024012195A (es) | 2024-11-08 |
| AU2023250874A1 (en) | 2024-10-10 |
| WO2023196361A1 (en) | 2023-10-12 |
| EP4504738A1 (en) | 2025-02-12 |
| US20240140966A1 (en) | 2024-05-02 |
| JP2025511331A (ja) | 2025-04-15 |
| TW202404982A (zh) | 2024-02-01 |
| CA3255077A1 (en) | 2023-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20078226A (es) | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas | |
| DOP2021000234A (es) | Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina | |
| CO2020015228A2 (es) | Sales de un inhibidor de fgfr | |
| CO2024012743A2 (es) | Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias | |
| MX2025000271A (es) | Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| CL2020002698A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| CL2022000093A1 (es) | Imidazopirimidinas como inhibidores de eed y uso de estas | |
| CO2021011919A2 (es) | Derivados de tieno[3,2-b] pirrol[3,2-d]piridazinona y uso de estos como derivados de pkm2 para el tratamiento del cáncer, la obesidad y trastornos relacionados con la diabetes | |
| CR7880A (es) | Derivados sustituidos de pirrolo-pirazol como inhibidores de quinasa | |
| CO2024012423A2 (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
| CL2024000446A1 (es) | Degradadores bifuncionales de quinasas asociadas al receptor de interleucina 1 y usos terapéuticos de los mismos. | |
| AR029215A1 (es) | Derivados de benzazol y tautomeros de los mismos utiles en el tratamiento de desordenes en los sistemas de autoinmunidad y neuronales, uso de dichos derivados en la preparacion de composiciones farmaceuticas aplicables en el tratamiento de dichos desordenes, metodo prar inhibir la expresion y/o acti | |
| AR061867A1 (es) | Derivados de (4,5') bipirimidil 6,4' - diamina como inhibidores de proteinquinasa | |
| MX2023005626A (es) | Derivados de pirazolo[1.5-a]pirazina como inhibidores de la btk. | |
| ES2141922T3 (es) | Tiazepinonas de benzotiofeno, benzofurano e indol, oxazepinonas y diazepinonas usadas como inhibidores de la adherencia celular y del vih. | |
| CY1109891T1 (el) | Παραγωγα ν-(αρυλαλκυλ)-1η-πυρρολοπυριδιν-2-καρβοξαμιδιων, η παρασκευη τους και η εφαρμογη τους σε θεραπειες | |
| CL2020002663A1 (es) | Compuestos moduladores alostéricos positivos gabaa, métodos de preparación y usos de los mismos | |
| MX2024012195A (es) | Formas amorfas y cristalinas de los antagonistas de mci-1 | |
| CO2026000531A2 (es) | Macrociclos para el tratamiento de enfermedades autoinmunitarias | |
| UY40217A (es) | Formas de sal y solvatos de antagonistas de mci-1 | |
| MX2022002839A (es) | Nuevo compuesto heterocíclico aromático tricíclico, método de preparación del mismo, composición farmacéutica y aplicación del mismo. | |
| CL2020002202A1 (es) | Derivados de 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7h-pirrolo [1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona y compuestos relacionados como inhibidores de la replicación del ortomixovirus para el tratamiento de la influenza | |
| MA53165A (fr) | Dérivés d'imidazo[1,2-b]pyridazine utilisés en tant qu'inhibiteurs de trk | |
| CO2025003259A2 (es) | Formulaciones que comprenden g-csf y usos de las mismas |